MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer

Gene

Volumn 506, Issue 2, 2012, Pages 404-407

  Dogu, Gamze Gokoz ^a   Kargi, Aysegul ^b   Turgut, Sebahat ^c   Ayada, Ceylan ^c   Taskoylu, Burcu Yapar ^a   Demiray, Gokcen ^a   Yaren, Arzu ^a   Ozlu, Can ^a   Temel, Sahin ^a   Ergin, Ahmet ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b DENIZLI STATE HOSPITAL   (Turkey)

^c PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

C3435T polymorphism; MDR1; Non small cell lung cancer (NSCLC); P glycoprotein; Platinum

Indexed keywords

ALBUMIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; FUNCTIONAL STATUS; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE 1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, GENETIC; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; TURKEY;

EID: 84864559628     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.06.057     Document Type: Article

References (23)

1. Ameyaw M.M., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11:217-221.
2. Bae S.Y., et al. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci. 2006, 97:774-779.
3. Brinkmann U., et al. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphism on pharmacotherapy. Drug Discov. Today 2001, 6:835-839.
4. Chen S. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int. J. Hyg. Environ. Health 2010, 213:140-145.
5. Fung K.L., Gottesman M.M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 2009, 1794:860-871.
6. Hoffmeyer S., et al. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3473-3478.
7. Isla D., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 2004, 15:1194-1203.
8. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
9. Klein I., et al. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1999, 1461:237-262.
10. Pan J.H., et al. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008, 75:380-385.
11. Pan J.H., et al. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2009, 78:49-55.
12. Ponez M., et al. Construction of human gene libraries from small amounts of peripheral blood. Hemoglobin 1982, 6:27-36.
13. Potocnik U., et al. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet. Cytogenet. 2008, 183:28-34.
14. Sakaeda T., et al. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 2002, 25:1391-1400.
15. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 1997, 8:161-170.
16. Sheng X., et al. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. Mol. Biol. Rep. 2012, 7237-7249.
17. Sohn J.W., et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn. J. Clin. Oncol. 2006, 36:137-141.
18. Spiro S.G., Silvestri G.A. The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med. 2005, 11:287-291.
19. Turgut S., et al. Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. Mol. Biol. Rep. 2006, 33:295-300.
20. Turgut S., et al. MDR1 C3435T polymorphism in patients with breast cancer. Arch. Med. Res. 2007, 38:539-544.
21. Viñolas N., et al. Spanish Lung Cancer Group. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011, 71:191-198.
22. Wei H.B., et al. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch. Med. Res. 2011, 42:412-420.
23. Yan P.W., et al. Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac. J. Cancer Prev. 2011, 12:2291-2294.